Genentech pioneered the biotechnology industry and revolutionized treatment for some of the most complex health problems. For nearly 50 years, the company has pursued groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer, Genentech has consistently pushed the boundaries of what is possible in biomedical research.
The company's transformational discoveries include the first personalized medicine for cancer and the first medicine for primary progressive multiple sclerosis. Today, Genentech operates as a member of the Roche Group, galvanizing the greatest minds across their business to make lasting improvements in healthcare. Their approach includes novel customer engagement strategies, state-of-the-art manufacturing facilities, and integrating AI for molecule discovery. With a $50 billion commitment to U.S. manufacturing and R&D, Genentech remains dedicated to leveling barriers to clinical trial participation, driving inclusive research, and optimizing health outcomes for all patients.
